Lenvima

CONTENTS

4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Lenvima : Hepatocellular carcinoma (HCC)
16 Lenvima : Renal cell carcinoma (RCC)

LIST OF FIGURES
11 Figure 1: Datamonitor Healthcare’s drug assessment summary of Lenvima for HCC
12 Figure 2: Datamonitor Healthcare’s drug assessment summary of Lenvima for HCC
14 Figure 3: Lenvima sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
22 Figure 4: Lenvima for RCC – SWOT analysis
23 Figure 5: Datamonitor Healthcare’s drug assessment summary of Lenvima for RCC
24 Figure 6: Datamonitor Healthcare’s drug assessment summary of Lenvima for RCC
26 Figure 7: Lenvima sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES
5 Table 1: Recent high-impact events for Lenvima in HCC
6 Table 2: Lenvima drug profile
7 Table 3: Approval history of Lenvima for HCC in the US, Japan, and five major EU markets
8 Table 4: Trials of Lenvima for HCC
10 Table 5: Lenvima for HCC – SWOT analysis
16 Table 6: Lenvima drug profile
18 Table 7: Lenvima pivotal trial data in RCC
20 Table 8: Lenvima ongoing trials in RCC
27 Table 9: Lenvima sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26